Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy ResponsePRNewsWire • 10/29/25
Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025PRNewsWire • 10/23/25
Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek®PRNewsWire • 08/15/25
New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer SubgroupsPRNewsWire • 08/13/25
Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live Almost Twice as Long as AI-negative Patients When Treated with a Checkpoint InhibitorPRNewsWire • 08/06/25
Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin Predictions are Best-in-Class and Identify when Patients have been MisdiagnosedPRNewsWire • 08/05/25
Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025PRNewsWire • 07/23/25
Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal HematopoiesisPRNewsWire • 07/22/25
Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy SelectionPRNewsWire • 07/08/25
U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 MillionSeeking Alpha • 06/22/25
Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debutFast Company • 06/18/25
Are You Looking for a Top Momentum Pick? Why CAI International (CAI) is a Great ChoiceZacks Investment Research • 02/23/21